Ravi Singh is a senior scientist at Sutro Biopharma with deep expertise in medicinal and synthetic organic chemistry, specializing in linker-payload design for antibody–drug conjugates (ADCs). Originally from rural India, Ravi began his scientific journey with degrees in chemistry and hands-on industry experience before pursuing a Ph.D. at the University of Texas at Arlington. Under Dr. Carl J. Lovely, he investigated the total synthesis of marine-derived natural products, focusing on spirocyclizations en route to Spirocalcaridines A and B.
At Sutro, Ravi contributes to the design and development of cleavable linkers, including PEGylated and β-glucuronidase-responsive systems, and brings strong expertise in payload synthesis, process scale-up, and analytical characterization. He has authored 10 peer-reviewed papers (7 as first author), reviewed 20 manuscripts, and has over 100 citations. In 2025, he co-chaired a workshop at the ADC Linker & Conjugation Summit, highlighting his leadership in the field.
Ravi’s career reflects a blend of grassroots training, academic rigor, and industrial innovation. His work bridges chemistry and biology to advance targeted cancer therapeutics and improve human health.
Ravi Singh is a senior scientist at Sutro Biopharma with deep expertise in medicinal and synthetic organic chemistry, specializing in linker-payload design for antibody–drug conjugates (ADCs). Originally from rural India, Ravi began his scientific journey with degrees in chemistry and hands-on industry experience before pursuing a Ph.D. at the University of Texas at Arlington. Under Dr. Carl J. Lovely, he investigated the total synthesis of marine-derived natural products, focusing on spirocyclizations en route to Spirocalcaridines A and B.
At Sutro, Ravi contributes to the design and development of cleavable linkers, including PEGylated and β-glucuronidase-responsive systems, and brings strong expertise in payload synthesis, process scale-up, and analytical characterization. He has authored 10 peer-reviewed papers (7 as first author), reviewed 20 manuscripts, and has over 100 citations. In 2025, he co-chaired a workshop at the ADC Linker & Conjugation Summit, highlighting his leadership in the field.
Ravi’s career reflects a blend of grassroots training, academic rigor, and industrial innovation. His work bridges chemistry and biology to advance targeted cancer therapeutics and improve human health.